A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07212751 |
Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE) |
ACTIVE_NOT_RECRUITING | |
| NCT01859897 |
A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan |
COMPLETED | |
| NCT01360073 |
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death |
COMPLETED | |
| NCT01360047 |
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death |
COMPLETED |
